Setting: A southern Myanmar district providing isoniazid preventive therapy (IPT) in one of the last countries to formally recommend it as part of human immunodeficiency virus (HIV) care. Objective: To assess coverage and adherence and the feasibility of IPT scale-up in a routine care setting in Myanmar. Design: A retrospective analysis of people living with HIV (PLHIV) screened for tuberculosis (TB) and enrolled in IPT over a 3-year period (July 2011-June 2014) using clinical databases. Results: Among 3377 patients under HIV care and screened for TB, 2740 (81.1%) initiated IPT, with 2651 (96.8%) completing a 6- or 9-month course of IPT; 83 (3.1%) interrupted treatment for different reasons, including loss to follow-up (n = 41), side effects (n = 15) or drug adherence issues (n = 9); 6 (0.2%) died. Among the IPT patients, 33 (1.2%) were diagnosed with TB, including 9 (0.3%) while on IPT and 24 (0.9%) within 1 year of completion of therapy. Among the PLHIV who completed IPT, one case of isoniazid resistance was detected. Conclusion: Scaling up IPT in Myanmar HIV settings is feasible with high rates of drug adherence and completion, and a low rate of discontinuation due to side effects. IPT scale-up should be prioritised in HIV clinical settings in Myanmar.
Setting: A southern Myanmar district providing isoniazid preventive therapy (IPT) in one of the last countries to formally recommend it as part of human immunodeficiency virus (HIV) care. Objective: To assess coverage and adherence and the feasibility of IPT scale-up in a routine care setting in Myanmar. Design: A retrospective analysis of people living with HIV (PLHIV) screened for tuberculosis (TB) and enrolled in IPT over a 3-year period (July 2011-June 2014) using clinical databases. Results: Among 3377 patients under HIV care and screened for TB, 2740 (81.1%) initiated IPT, with 2651 (96.8%) completing a 6- or 9-month course of IPT; 83 (3.1%) interrupted treatment for different reasons, including loss to follow-up (n = 41), side effects (n = 15) or drug adherence issues (n = 9); 6 (0.2%) died. Among the IPTpatients, 33 (1.2%) were diagnosed with TB, including 9 (0.3%) while on IPT and 24 (0.9%) within 1 year of completion of therapy. Among the PLHIV who completed IPT, one case of isoniazid resistance was detected. Conclusion: Scaling up IPT in Myanmar HIV settings is feasible with high rates of drug adherence and completion, and a low rate of discontinuation due to side effects. IPT scale-up should be prioritised in HIV clinical settings in Myanmar.
Authors: P M Namuwenge; J K Mukonzo; N Kiwanuka; R Wanyenze; R Byaruhanga; K Bissell; R Zachariah Journal: Trans R Soc Trop Med Hyg Date: 2011-12-10 Impact factor: 2.184
Authors: Haileyesus Getahun; Reuben Granich; Delphine Sculier; Christian Gunneberg; Leopold Blanc; Paul Nunn; Mario Raviglione Journal: AIDS Date: 2010-11 Impact factor: 4.177
Authors: David W Dowdy; Jonathan E Golub; Valeria Saraceni; Lawrence H Moulton; Solange C Cavalcante; Silvia Cohn; Antonio G Pacheco; Richard E Chaisson; Betina Durovni Journal: J Acquir Immune Defic Syndr Date: 2014-08-15 Impact factor: 3.731
Authors: Thuy T Trinh; Dien T Han; Emily Bloss; Thai H Le; Tung T Vu; Anh H Mai; Nhung V Nguyen; Long T Nguyen; Sy N Dinh; Sara Whitehead Journal: Trans R Soc Trop Med Hyg Date: 2015-10 Impact factor: 2.184
Authors: Mai T Pho; Soumya Swaminathan; Nagalingeswaran Kumarasamy; Elena Losina; C Ponnuraja; Lauren M Uhler; Callie A Scott; Kenneth H Mayer; Kenneth A Freedberg; Rochelle P Walensky Journal: PLoS One Date: 2012-04-30 Impact factor: 3.240
Authors: Masanja Robert; Jim Todd; Bernard J Ngowi; Sia E Msuya; Angella Ramadhani; Veryhel Sambu; Isaya Jerry; Martin R Mujuni; Michael J Mahande; James S Ngocho; Werner Maokola Journal: BMC Infect Dis Date: 2020-04-10 Impact factor: 3.090
Authors: Mahendra M Reddy; Pruthu Thekkur; Nagesh Ramya; Prasanna B T Kamath; Suresh G Shastri; Ravi B N Kumar; Palanivel Chinnakali; Abhay S Nirgude; Chethana Rangaraju; Narasimhaiah Somashekar; Ajay M V Kumar Journal: Glob Health Action Date: 2020 Impact factor: 2.640
Authors: Muthoni Karanja; Leonard Kingwara; Philip Owiti; Elvis Kirui; Faith Ngari; Richard Kiplimo; Maurice Maina; Enos Masini; Elizabeth Onyango; Catherine Ngugi Journal: PLoS One Date: 2020-12-02 Impact factor: 3.240